Rapport Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Rapport Therapeutics, Inc. (RAPP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.20M, a 64.09% increase year-over-year.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.96M, a 72.35% increase year-over-year.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.74M, a 48.81% increase year-over-year.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.39M, a 86.45% increase year-over-year.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.86M, a 84.22% increase from fiscal 2024.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.23M, a 190.35% increase from fiscal 2023.
- Rapport Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.52M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.20M 10-Q · filed 2026-08-05 | $14.16M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $6.96M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $18.86M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $4.74M 10-Q · filed 2025-11-06 | $9.12M derived: sum of 2 quarters · filed 2026-08-05 | $13.16M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $4.39M 10-Q · filed 2026-08-05 | $8.43M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $4.04M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $10.23M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $3.18M 10-Q · filed 2025-11-06 | $5.54M derived: sum of 2 quarters · filed 2025-11-06 | $7.03M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.35M 10-Q · filed 2025-11-06 | $3.85M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $1.49M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $3.52M 10-K · filed 2025-03-11 | |||
| 2023-06-30 | $945.00K 10-Q · filed 2024-11-07 | $1.67M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $723.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |